The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

Although combination therapy with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib (MLN8237) resulted in marginal clinical benefit among patients with advanced solid tumors, correlative analyses indicated that apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.